A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and Efficacy

Completed · Phase 1/Phase 2

Conditions studied: Parkinson's Disease

In brief

This study will investigate the effect of TCH346 compared to placebo in delaying the need for symptomatic treatment with dopaminergic agents

Key facts

Study ID

NCT00407212

Run by

Novartis

People needed

301

Starts

2002-01-01

Expected to finish

2003-11-01

Last updated by the study team

2011-11-23

Who can join

Age: 30 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female ,aged 30-80 years
• Clinical diagnosis of early stage idiopathic Parkinson's disease
• Experiencing two of the three following signs; bradykinesia, rigidity, and tremor
• Not currently taking any antiparkinson medication

You may not qualify if…

• A history of alcohol or drug abuse in the past year
• A diagnosis psychiatric illness
• Patients who currently are taking MAO inhibitors within 30 days of entering the study
• Patients who are hypersensitive to selegiline, MAO-B inhibitors, or tricyclic antidepressants
• Additional inclusion/exclusion criteria may apply

Where it is running

• Study site — Phoenix, Arizona, United States
• Study site — Berkley, California, United States
• Study site — Fountain Valley, California, United States
• Study site — Sunnyvale, California, United States
• Study site — New Haven, Connecticut, United States
• Study site — Chicago, Illinois, United States
• Study site — Southfield, Michigan, United States
• Study site — Great Falls, Montana, United States
• Study site — Columbus, Ohio, United States
• Study site — Pawtucket, Rhode Island, United States
• Study site — Houston, Texas, United States
• Novartis Investigative Site — Belo Horizonte, Brazil
• Novartis Investigative Site — Curitiba, Brazil
• Novartis Investigative Site — Fortaleza, Brazil
• Novartis Investigative Site — São Paulo, Brazil
• Novartis Investigative Site — Caligary, Canada
• Novartis Investigative Site — Hallifax, Canada
• Novartis Investigative Site — Markham, Canada
• Novartis Investigative Site — Montreal, Canada
• Novartis Investigative Site — Vancouver, Canada
• Novartis Investigative Site — Winnipeg, Canada
• Novartis Investigative Site — Clermont, France
• Study site — Marseille, France
• Novartis Investigative Site — Paris, France
• Study site — Saint-Herblain, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.